Thrombophilia and hypercoagulable status which promote the formation of blood clots may occlude the pre-existed stenotic segments in AV access and even in the native nonstenotic AV access. Some genotype polymorphisms were demonstrated to be associated with hypercoagulable status, including methylene tetrahydrofolate reductase (MTHFR), coagulation factors (factor XIII, prothrombin, factor V Leiden), and heme oxygenase-1 (HO-1). On the contrary, stenosis of AV access may come from the etiologies of endothelial dysfunction, intimal hyperplasia, and chronic inflammation. Other than the uremic milieu, some genotype polymorphisms may be associated with above pathogenic effects and lead to increase susceptibility of AV access stenosis. These genotype polymorphisms include genes encode HO-1, matrix metalloproteinase (MMP), transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α), vascular endothelial growth factor-A (VEGF-A), renin-angiotensin-aldosterone system (RAAS), and protein methyl transferase (PRMT1). The details of the association between each genotype polymorphism and AV access dysfunction will be discussed and summarized in Table 1 .
Methylentetrahydrofolate reductase
Methylentetrahydrofolate reductase (MTHFR) is a key enzyme in the methyl cycle which mediates the remethylation of homocysteine to methionine. Mutation of MTHFR may be associated with increasing plasma homocysteine level and increase the risk of cardiovascular disease. 20 In addition, the MTHFR C677T polymorphism was also reported to be associated with AVF malfunction. 2 Fukasawa et al. conducted a cross-sectional design study that enrolled 337 HD patients with native AVFs to examine whether there was a relationship between MTHFR C677T polymorphism and AVF obstruction. Distribution of three genotypes including CC, CT, and TT was 32.9%, 46.9%, and 20.1%, respectively. Patients with genotype TT and CT tended to have a higher odds ratio (OR) of 3.16 (95% confidence interval (CI): 1.50-6.65) and 1.77 (95% CI: 0.90-3.50) for AVF obstruction as compared with the genotype CC. Multivariate logistic regression also showed that the genetic polymorphism of MTHFR was the only relevant factor predicting AVF obstruction with the OR of 1.769 for T-allele-containing genotypes of MTHFR. 2 However, another study conducted by Mallamaci et al. 3 showed that the MTHFR C677T polymorphism failed to predict outcome of AVF. This prospective cohort study enrolled 205 White HD patients with native AVF to examine the relationship between plasma homocysteine, MTHFR C677T genotype polymorphism, and AVF outcome. Distribution of three genotypes of CC, CT, and TT was 37%, 51%, and 12%, respectively. The hazard ratio (HR) for AVF thrombosis increased in parallel with plasma homocysteine level, and patients in the third plasma homocysteine tertile had a relative risk of 1.72 for AVF outcome in comparison with patients in the first tertile. Despite plasma homocysteine level was significantly higher among patients with TT genotype of the MTHFR gene when compared with those with the CT or CC genotype, the frequency of AVF thrombosis was not significantly different between patients with CT or TT genotype in comparison with those with CC genotype (33% vs 32%).
Whether patients harboring MTHFR C677T genotype polymorphism increases the susceptibility to vascular access thrombosis or not still needs to be clarified. However, the recent large-scale meta-analysis from Cochrane Database Systemic Review found homocysteine-lowering therapy provides no significant benefits to reduce all-cause mortality, incident cardiovascular disease, cerebrovascular disease, peripheral vascular disease, venous thromboembolic disease, and thrombosis of dialysis access. 21 
Coagulation factors
Genetic mutation in the coagulation cascade impairs normal coagulation and may induce serial thromboembolic events. Several studies were conducted aiming to evaluate the association between genotype polymorphism of genes encoding coagulation factors and the incidence of vascular access thrombosis.
Knoll et al. 6 had conducted a case-control study that enrolled 107 HD patients with a history of dialysis access thrombosis and a control group with 312 HD patients never experienced access thrombosis. The study evaluates the association of vascular access thrombosis and single nucleotide polymorphism (SNP) of genes in coagulation cascades, including factor V Leiden, factor XIII (Val34Leu), prothrombin (G20210A), and MTHFR (C677T). Unadjusted OR for VA thrombosis was 1.91 with the presence of any of above SNPs, and the OR elevated to 2.42 after adjusting factor XIII and other risk factors. Besides, the OR increases 1.87 for each additional thrombophilia, and SNP of factor V Leiden showed highest OR of 3.94 after adjusting for each individual thrombophilia and other risk factors. Another study conducted by Verschuren et al. enrolled 479 incident HD patients with AVF to examine 43 SNPs in 26 genes which related to cell proliferation, inflammation, endothelial function, vascular remodeling, coagulation, and mineral bone metabolism. 4 Only two SNPs were associated with an increased risk of AVF failure, including factor V Leiden rs6025 with an HR of 2.54 and low-density lipoprotein (LDL) receptor-related protein 1 (LRP1) rs1466535 with an HR of 1.75. Allon et al. also conducted a study that enrolled 354 HD patients with a new created AVG and obtained DNA samples to examine the relationship between genotype polymorphism and graft failure. Only SNP of factor V rs6019 was significantly associated with graft failure in a dominant model with HR of 1.70 for G/C and G/G genotypes versus C/C genotypes. 5 Other than the genes which encode coagulation factors, some mediators in the coagulation were also examined for the probability to influence the incidence of vascular access thrombosis. SNPs of human platelet antigen-3 (HPA-3) (aa genotype vs ab and bb genotypes), HPA-4 (4a4b genotype vs 4a4a genotype), and plasminogen activator inhibitor 1 (PAI-1) (4G/5G genotype vs 4G/4G genotype) were found to be associated with increasing risk of AVF thrombosis with the OR of 3.58, 45.6, and 5.03, respectively. 7-9
HO-1
The gene encoding HO-1 is located at chromosome 22q12, and HO-1 is a rate-limiting enzyme which catalyzes and degrades intracellular heme into equimolar quantities of biliverdin, free ion and CO. 22, 23 In vivo, HO-1 acts as a stress-response protein and is crucial for growth regulation, cell proliferation, cell death (apoptosis), and cell hypertrophy. The regulatory functions may mediate via the metabolites of heme, CO, and biliverdin which is subsequently metabolized to bilirubin by biliverdin reductase. CO works in the manner of autocrine to inhibit vascular smooth muscle cell (VSMC) proliferation, in the manner of paracrine to inhibit the release of vascular mitogens from circulating platelets and their adjacent endothelial cells (ECs), and is endocrine-like to participate in the process of "re-endothelialization" of vessel wall at the site of vascular injury. 24 Biliverdin and bilirubin may aggravate the loss of VSMCs in injured vascular walls by prompting VSMC apoptosis. The length polymorphism of HO-1 gene manifests as a variable length of repeated (GT) n dinucleotide in the proximal promotor region. Longer GT repeats of HO-1 gene might limit its transcription which in turn abate the important protective effect against vascular injury. 22 We had conducted a study that enrolled 603 HD patients to examine the relationship between length polymorphism of HO-1 and AVF failure. 10 Long allele (L) is defined as GT repeat number of equal to or more than 30 while short allele (S) is defined as GT repeat number of less than 30. The study demonstrated that length polymorphism of HO-1 was associated with the frequency of AVF failure with the failure rate of 20.3%, 31%, and 35.4% in patients with S/S, S/L, and L/L alleles, respectively. In addition, the unassisted patency of AVF at 5 years was also influenced with the patency rate of 83.8%, 75.1%, and 69% in patients with S/S, S/L, and L/L alleles, respectively. Patients with L/L and L/S alleles of HO-1 existed a higher HR of 2.04 as compared with those with S/S alleles in the rate of AVF failure. For the second outcomes, HD patients with L/L and L/S alleles had a higher prevalence of coronary artery disease (29.1 vs 14.2%) and cardiovascular disease (33.5 vs 20.3%) when compared with those with S/S alleles.
Treatment with far infrared (FIR) irradiation could exert a potent anti-inflammatory effect via the induction of HO-1 on cultured human umbilical vein ECs. 25 We had demonstrated that treatment of FIR irradiation may increase the maturation and survival of AVF in HD patients. 26, 27 Besides, Lai et al. 28 also demonstrated that FIR could improve postangioplasty 1-year unassisted patency of AVG in HD patients. The positive results of interventions aimed to increase the expression of HO-1 further strengthened the relationship between HO-1 polymorphism and vascular access dysfunction in HD patients
MMP
MMP is an enzyme that hydrolyzes the extracellular matrix (ECM), associated with VSMC migration and ECM degradation.
We had conducted a study that enrolled 596 HD patients to examine the relationship between genotype polymorphism of MMPs and the frequency of AVF failure. Specific genotypes of MMP-1, MMP-3, and MMP-9 with lower transcriptional activity, including 1G/1G genotype of MMP-1 −1607 1G>2G SNP, 6A/6A genotype of the MMP-3 −1612 5A>6A SNP, and C/C genotype of the MMP-9 −1562 C>T SNP, were linked to higher frequency of AVF failure with HR of 2.315, 1.712, and 1.650, respectively. 11 The unassisted patency of AVF at 5 years also decreased significantly from 72.2% to 55.2% in patients with 1G/1G genotypes of MMP-1 −1607, from 77.3% to 67.9% in patients with 6A/6A genotypes of MMP-3 −1612, from 79.0% to 67.1% in those with C/C genotypes of MMP-9 −1562, and from 93.3% in patients with 2G-/5A-/T-allele-containing genotypes to 38.4% in those with 1G1G/6A6A/CC genotypes.
Patients with these genotypes may be more susceptible to intravascular accumulation of ECM, which narrows the luminal diameter of AVF and slows the access flow (Qa), which consequently raise the risk of AVF failure.
TGF-β1
TGF-β1 is associated with intimal hyperplasia, VSMC proliferation and migration, and excess accumulation of ECM. 29 Being one of the most mediators in the formation of vascular access stenosis, the synthesis of TGF-β1 protein differs due to two SNP (polymorphic bases at positions 869 and 915) in the DNA sequence encoding the signal sequence of TGF-β1 protein. 30 Heine et al. 12 had conducted a study that enrolled 120 HD patients with AVF to examine the relationship between the SNP at positions 869 and 915 of the TGF-β1 gene and the patency of AVF. The patients were divided into three groups: TGF-β1 high, intermediate, and low producers according to both SNPs. The 12-month patency of AVF was significantly associated with the TGF-β1 genotype with the patency of 62.4% in high producers and of 81.2% in intermediate producers. The HR was 2.63 for high producers when compared with intermediate producers for AVF failure.
TNF-α
TNF-α, a cytokine that initiates systemic inflammation and regulates the function immune cells, may highly involve the postinjury intimal hyperplasia resulting in vascular access stenosis. 31 An SNP located at position 308 (G>A) of TNF-α promoter gene is associated with enhanced production of TNF-α and increasing the susceptibility to several systemic diseases. 32, 33 In addition, Sener et al. 13 also demonstrated that TNF-α −308 G>A gene polymorphism was associated with higher risk of AVF thrombosis. The study enrolled 47 HD patients with AVF thrombosis, 51 HD patients without AVF thrombosis, and 40 healthy controls to examine the relationship between TNF-α −308 G>A polymorphism and AVF thrombosis. The genotype distribution of TNF-α −308 G>A in patients with thrombosis was significantly different from the patients without thrombosis, with the OR of 4.20 in G/A genotype compared with G/G genotype.
Another study conducted by Ram et al. 14 enrolled 67 HD patients with AVG to examine the relationship between high-(G/A, A/A) and low-production TNF-α genotype and the rate of graft patency. High-production genotypes had a significantly increased graft failure rate at 90 days (37.2% vs 14%) and 1 year (62.8% vs 34.4%) after graft placement compared with low-production genotype. Patients with the high-production TNF-α genotypes exhibits approximately twofold higher mean thrombosis rate than those with low-production genotype (3.3 ± 0.8 vs 1.7 ± 0.4 thromboses/patient/year).
VEGF-A
VEGF-A is reported to be associated with acceleration of re-endothelialization and reduction of intimal thickening in the injured vessels. VEGF-A could bind to vascular endothelial growth factor receptor-2 (VEGFR-2) which mediates endothelial growth and survival, but it could also bind to VEGF receptor-1 (VEGFR-1) which mediates the pathologic response including ischemia and inflammation. 34 In addition, VEGF-A may stimulate the increase of tissue factor initiating coagulation and leading to the development of stenotic lesions of vessel.
An SNP of VEGF 936 gene (C/C genotype) was demonstrated to increase the risk of AVF thrombosis. Candan et al. 15 had conducted a study that enrolled 42 HD patients with AVF failure (patient group) and 38 patients without AVF failure (control group) to evaluate both the VEGF 936 gene polymorphism and VEGF-A levels in order to elucidate their association with AVF loss in HD patients. Patients harboring VEGF −936 C/C genotype was 90.5% in patient group and exhibited an increased risk of AVF thrombosis with OR of 5.54. Besides, the patient group had a significantly lower VEGF-A levels (27.3 ± 43.5 pg/ mL) compared with the control group (70.7 ± 53.1 pg/mL). However, there was no significant difference of VEGF-A level between VEGF-936C/C and VEGF-936C/T in both groups. The author suggested that thrombotic AVF might existed more VSMCs and stimulate more sVEGFR-1 production which binds and degrades VEGF-A, resulting in lower VEGF-A level. The limitation of study was lacking the exact level of both sVEGFR-1 and sVEGFR-2 which could support the hypothesis of the authors.
RAAS
RAAS exerts an important role in modulating the homeostasis of fluid and electrolyte and the balance of hemodynamics. Besides, it also plays a crucial role in promoting vascular inflammation and remodeling, leading to endothelial dysfunction and increased susceptibility to thrombosis and stenosis of vascular access. 35 Despite the hypothesis highly links the expression of RAAS and the pathogenesis of thromboembolic events, however, serial investigations aimed to examine the relationship between genetic polymorphism of angiotensin-converting enzyme (ACE) or angiotensin II receptor 1/2 (AGTR1/2) and AVF thrombosis showed controversial results. 9, 17, [36] [37] [38] [39] Chen et al. 16 had conducted a study that enrolled 154 HD patients with AVF malfunction and 423 HD patients without AVF malfunction to examine the relationship between SNPs of RAAS genes (including angiotensinogen, ACE, AGTR1, and AGTR2) and AVF thrombosis. Only minor allele-containing SNP (AA and CA) of AGTR1 gene, rs1492099 (intron (IVS2 +11689), was demonstrated to be a significantly genetic risk factor of AVF malfunction with OR of 3.63 in male HD patients. Nevertheless, none of SNPs of AGT, ACE, AGTR2, and AGTR1 in female patients had been a significant risk factor of AVF malfunction. Komukai et al. 40 suggested that the intersexual difference might come from the protective effect of estrogen which lowers the AGT1R but increases AGT2R density. Prospective randomized study using intervention of RAAS blockade agents may be needed to further elucidate the relationship between SNP of AGT1R and AVF malfunction.
Nitric oxide synthase and protein methyl transferase 1
Endothelial nitric oxide synthase (NOS) mediates the production of NO which is associated with vasodilation in response to shear stress and free radical scavenging to prevent extensive vascular remodeling in injured vessels. 41 Reduced abundance or activity of endothelial NO may impair the natural defense mechanism for vascular injury and be associated with vascular access dysfunction. 41 Asymmetric dimethylarginine (ADMA) is synthesized by PRMT and is enzymatically degraded by dimethylarginine dimethyl aminohydrolase (DDAH1 and DDAH2). ADMA may inhibit the normal function of endothelial NOS, thus reducing the synthesis of NO, and increased plasma ADMA is a risk factor of cardiovascular disease in patients with ESRD. 42 Lee et al. 19 had conducted a study that enrolled 161 HD patients with AVF malfunction and 419 HD patients without AVF malfunction to examine the relationship between NO-related genotype polymorphisms and AVF malfunction. An SNP of PRMT1, rs10415880 (IVS9-193 A/G), was significantly associated with AVF malfunction in male HD patients with the OR of 4.05. As compared with patients harboring GG genotype of PRMT1, those with AA and AG genotypes exhibited a lower AVF survival including lower primary patency (70.6% vs 40.9%), lower assisted primary patency (81.0% vs 58.41), and lower secondary patency (83.7% vs 63.3%) at a 5-year observation period.
The AA and AG genotypes of PRMT1 were an independent relevant factor for AVF malfunction in men with the HR of 4.539 and could predict a poorer long-term patency of AVF in male HD patients.
Conclusion
Despite current evidence demonstrated that above-mentioned genotype polymorphisms being associated with AV access dysfunction, however, further prospective study is imperative to confirm the association. Elucidating the association between the genotype polymorphisms and the outcome of vascular access will be contributive in the medical therapy to improve vascular access patency. The best example is the utilization of FIR therapy, which exerts a potent anti-inflammatory effect via the induction of HO-1, significantly increased the patency of vascular access. [25] [26] [27] 43 More and more therapeutic options that focus on genotype polymorphisms could be expected in the future and may generate a great benefit to the patency of vascular access of uremic patients.
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